Overview

The Indy Hematology Review™ annually offers a crucial and advanced educational and scientific meeting for hematology professionals. Join others at the Review to examine the current conclusions from leading hematology researchers and educators as they discuss the most recent advances to improve patient management and care. Data from major hematology and oncology conferences of the past year, including the American Society of Hematology, American Society of Clinical Oncology and the European Hematology Association Congress will be reviewed in a fast-paced interactive format, all within a comfortable and collaborative setting. The Review features broad clinical content, an opportunity to interact with colleagues in a setting with no competing sessions and to discuss out-of-the-box treatments that organically lead to stimulating conversations on specific disease topics throughout the day and during the Town Hall.

Learning Objectives

Upon completion of this activity, the participant should be able to:

1. Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies.
2. Evaluate the best treatment options for newly diagnosed AML patients.
3. Identify the emerging therapies Myelodysplastic Syndromes and Acute Lymphoblastic Leukemias and discuss how to put these treatment options into practice.
4. Describe treatment options for managing patients with Chronic Myeloid Leukemia in the current landscape.
5. Identify the new treatment options for Myeloid and Lymphoblastic Leukemias and describe how to put these treatment options into practice.
6. Discuss the emerging treatment options for newly diagnosed with Multiple Myeloma and describe how to put these treatment options into practice.
7. Implement the emerging treatment approaches for patients with Relapsed / Refractory Multiple Myeloma and describe how to put these treatment options into practice.
8. Describe the most current treatment options for Waldenstrom’s Macroglobulinemia.
9. Adjust their diagnostic and treatment strategies for patients with Amyloidosis to include the latest options beyond Anti-CD38 Antibody therapy.
10. Implement current guidance for the diagnosis and treatment of patients with Complementopathies.
11. Discuss current treatment options for patients with Aplastic Anemia.
12. Describe best practices in the management of patients with classical bleeding and clotting disorders.
13. Identify the most effective cellular therapies needed to manage Sickle Cell Disease.
14. Treat Mantle Cell Lymphomas while navigating the current controversies in managing this disease.
15. Implement optimal treatment strategies for patients with Myeloproliferative Neoplasms in their practice.
16. Improve the management of patients with Chronic Lymphocytic Leukemia in their practice
17. Identify the emerging treatment options for Indolent Lymphoma and describe how to implement these treatment options in practice.
18. Explain how to effectively implement new therapies for Hodgkin Lymphoma.
19. Evaluate the best therapies for treating Aggressive B and T Cell Lymphomas.
20. Explain when to utilize cellular and Bispecific Antibody Therapy in the treatment of patients with Lymphoid Malignancies.
21. Describe how to implement Immune Effector therapies for patients with Multiple Myeloma.
22. Identify the optimal scenarios and timing to refer patients for Hematopoietic transplantation or cellular therapies.

Accreditation

Purdue University College of Pharmacy designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Symposium – 7:30 am – 7:20 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ (Town Hall Interactive Meeting – 7:40 - 8:40 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.